+

WO1999038502A1 - Utilisations pharmaceutiques de (+)-bupropion optiquement pur - Google Patents

Utilisations pharmaceutiques de (+)-bupropion optiquement pur Download PDF

Info

Publication number
WO1999038502A1
WO1999038502A1 PCT/US1999/001952 US9901952W WO9938502A1 WO 1999038502 A1 WO1999038502 A1 WO 1999038502A1 US 9901952 W US9901952 W US 9901952W WO 9938502 A1 WO9938502 A1 WO 9938502A1
Authority
WO
WIPO (PCT)
Prior art keywords
bupropion
administered
amount
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US1999/001952
Other languages
English (en)
Inventor
James W. Young
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22110794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999038502(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Priority to CA002318960A priority Critical patent/CA2318960A1/fr
Priority to AU24834/99A priority patent/AU2483499A/en
Priority to EP99904433A priority patent/EP1051166A1/fr
Priority to JP2000529235A priority patent/JP2002501890A/ja
Publication of WO1999038502A1 publication Critical patent/WO1999038502A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • This invention relates to methods of treatment and pharmaceutical compositions employing the compound (+) - bupropion.
  • Stereochemical purity is of importance in the field of pharmaceuticals, where 16 of the 20 most prescribed drugs exhibit chirality.
  • a case in point is provided by the L-form of the ⁇ -adrenergic blocking agent, propranolol, which is known to be 100 times more potent than the D-enantiomer .
  • the D- enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, while the corresponding L-enantiomer was a potent teratogen.
  • Bupropion is available only as a racemic mixture called Wellbutrin ® and ellbutrin SR ® (for depression) , and Zyban ® (to achieve smoking cessation) . That is, bupropion is available as a mixture of optical isomers, called enantiomers .
  • the racemic mixture of bupropion which is commercially available is administered as a hydrochloride salt.
  • Affective disorders including major depression, and the bipolar, manic-depressive illness, are characterized by changes in mood as the primary clinical manifestation.
  • Major depression is the most common of the significant mental illnesses, and it must be distinguished clinically from periods of normal grief, sadness and disappointment, and the related dysphoria or demoralization frequently associated with medical illness.
  • Depression is characterized by feelings of intense sadness, and despair, mental slowing and loss of concentration, pessimistic worry, agitation, and self-deprecation.
  • Physical changes can also occur, including insomnia, anorexia, and weight loss, decreased energy and libido, and disruption of hormonal circadian rhythms. Often the condition responds well to tricyclic or related antidepressant drugs, monoamine oxidase inhibitors, or in resistant cases or severe disease, to electro-convulsive shock treatment .
  • bupropion has been demonstrated to be an effective treatment in depression m short-term and longer duration clinical studies .
  • the racemic mixture of bupropion has been reported to have an antidepressant activity equal to amitriptylme, the tricyclic antidepressant, with fewer anticholmergic, sedative and cardiovascular side effects than with amitriptylme .
  • Parkinson's disease independent of a specific etiology, is a chronic, progressive central nervous system disorder which usually appears insidiously in the latter decades of life. The disease produces a slowly increasing disability m purposeful movement. It is characterized by four manor clinical features of tremor, bradykmesia, rigidity and a disturbance of posture. Often patients have an accompanying dementia. In ldiopathic Parkmsonism, there is usually a loss of cells in the substantia nigra, locus ceruleus, and other pigmented neurons of the brain, and a decrease of dopamme content in nerve axon terminals of cells projecting from the substantia nigra .
  • Parkmsonism is a syndrome of dopamme deficiency and the discovery of levodopa as an important drug for the treatment of the disease were the logical culmination of a series of related basic and clinical observations, which serves as the rationale for drug treatment.
  • ADD Attention-deficit disorder
  • Symptoms and signs include hyperactivity (e.g. , ADDH and AD/HD, DSM-IV) , impulsivity, emotional lability, motor incoordination and some perceptual difficulties.
  • Treatment has included psychostimulants, which while effective are controversial, and may cause troubling side effects such as dysphoria, headache and growth retardation.
  • Other drugs including the tricyclic antidepressants, appear to improve attention, but may be less effective than the psychostimulants .
  • Bupropion has been shown to be effective in children with attention-deficit disorder or conduct disorder thus improving the symptoms of anxiety, hostility and uncooperativeness, antisocial behavior, as well as eating disturbances. The drug has also demonstrated activity in cases of psycho-sexual dysfunction and bulimia.
  • bupropion is contra-indicated in patients with a seizure disorder, or a current or prior diagnosis of bulimia or anorexia nervosa characterized by a disturbed sense of body image and abnormally high anxiety about weight gain. It has been suggested that the racemic mixture of bupropion could be used to assist in weight loss. Treatment with bupropion is consistently associated with a lack of weight gain. Also bupropion reduces episodes of binge eating and purging. Although the mechanism by which bupropion causes weight loss is uncertain, an increase in the activity of the patient may play some part together with subtle changes in food intake and metabolism.
  • the causes of excess body weight and/or obesity are complex; however, a common denominator in the overweight person's diet is a caloric intake which exceeds that person's body expenditures.
  • One method of treating a person who is overweight and/or obese is to restrict that person's caloric intake, in combination with an exercise regimen. This method may be limited in its effectiveness since many overweight or obese people have developed eating and activity patterns which are counterproductive to achieving weight reduction.
  • Another method to treat overweight or obese patients is to administer appetite suppressant drugs in conjunction with a weight reduction program. The drawback to this method is that many appetite suppressant drugs produce undesirable adverse effects which limit their usefulness.
  • the racemic mixture of bupropion in addition to its use in the treatment of depression and the other above- mentioned disorders, has been shown to have a wide spectrum of action which includes:
  • bupropion does not inhibit monoamine oxidase, or block the reuptake of serotonin.
  • the compound presumably does not bind to adrenergic, dopamine, GABA, histamine, muscarinic, serotonin, or imipramine binding sites. While its specific
  • racemic mixture of bupropion has advantages, it also has disadvantages. Among these disadvantages are adverse effects in addition to those described above . The most serious adverse effect associated with the racemic mixture of bupropion is the increased incidence of seizures. In addition, other frequently reported adverse effects associated with the use of racemic bupropion include nausea, vomiting, excitement, agitation, blurred vision, restlessness, postural tremor, and some hallucinations/confusional states with the potential for abuse.
  • racemic mixture of bupropion include but are not limited to anxiety, insomnia, headaches and/or migraines, dry mouth, constipation, tremor, sleeping disturbances, dermatologic problems (e.g. , rashes) , neuropsychiatric signs and symptoms (e.g. , delusions and paranoia) , and weight loss or gain. See, the Physician's Desk Reference ® (1998). These effects are dose limiting in a number of patients. In Parkinsonian patients, the adverse effects can be the particular toxicity of the racemic mixture of bupropion or the result of a drug interaction (as most patients were receiving concomitant levodopa) .
  • the active compound of compositions and methods disclosed herein is an optical isomer of the compound bupropion which is described m United States Patent Nos . 3,819,706 and 3,885,046. Chemically, this isomer is (+)-2- (tertbutylam o) -3'-chloroprop ⁇ ophenone or (+)-l-(3- chlorophenyl) -2 [ (1, 1 -dimethyl -ethyl) ammo] -1-propanone.
  • This isomer will hereinafter be referred to as "(+) -bupropion” , which also includes the substantially optically pure (+) - bupropion isomer.
  • (+) -bupropion is an effective antidepressant which is useful in treating depression in humans.
  • (+) -bupropion can be used to treat depression while avoiding adverse effects including but not limited to seizures, agitation, dry mouth, insomnia, headache/migraine, nausea, dizziness, tachycardia, vomiting, constipation, and tremor associated with the racemic mixture of bupropion.
  • (+) -bupropion and pharmaceutical compositions containing optically pure (+) -bupropion are useful m treating weight gam or obesity.
  • the optically pure (+) -isomer of bupropion is useful m the treatment of Parkinson's disease.
  • the optically pure (+) -isomer is useful in the treatment of other disorders including but not limited to bipolar disorders, attention-deficit disorders, conduct disorders, psycho-sexual dysfunction, bulimia, eating disorders and specific food cravings .
  • the present invention also includes methods for treating the above-described conditions a human while avoiding adverse effects that are associated with the racemic mixture of bupropion, by administering the optically pure (+) -isomer of bupropion to said human.
  • the present invention encompasses a method of treating depression in a human while avoiding the concomitant liability of adverse effects associated with the administration of racemic bupropion which comprises administering to said human in need of antidepressant therapy, an amount of (+) -bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-)- stereoisomer, said amount being sufficient to alleviate depression, but ' insufficient to cause adverse effects associated with racemic bupropion.
  • the present invention also encompasses pharmaceutical compositions for the treatment of humans which comprises a therapeutically effective amount of (+) -bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-) -stereoisomer, and a pharmaceutically acceptable carrier.
  • pharmaceutical compositions are those which have a means for controlled sustained release of the active ingredient, (+) -bupropion.
  • the present invention further encompasses a method of treating Parkinson's disease in a human while avoiding the concomitant liability of adverse effects associated with the administration of racemic bupropion, which comprises administering to said human suffering from Parkinson's disease, an amount of (+) -bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (-)- stereoisomer, said amount being sufficient to alleviate said condition, but insufficient to cause adverse effects associated with administration of racemic bupropion.
  • the present invention encompasses a method of treating obesity or weight gain in a human, which comprises administering to said human in need of a reduction in weight, an amount of (+) -bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-)- stereoisomer, said amount being sufficient to reduce weight or prevent weight gain, but insufficient to cause adverse effects associated with administration of racemic bupropion.
  • the present invention also encompasses a method of treating disorders including, but not limited to, bipolar disorders, attention-deficit disorders, conduct disorders, psycho-sexual dysfunction, bulimia, eating disorders and specific food cravings in humans while avoiding the concomitant liability of adverse affects associated with the administration of racemic bupropion, which comprises administering to a human in need of such therapy a therapeutically effective amount of (+) -bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (-) -stereoisomer .
  • the racemic mixture of bupropion (i.e. , approximately a 50:50 mixture of its two enantiomers) causes antidepressant activity and provides therapy and/or reduction of symptoms in a variety of conditions and disorders; however, this racemic mixture, while offering the expectation of efficacy, causes a broad range of adverse effects. Utilizing the optically pure (+) -isomer of bupropion results in clearer dose-related definitions of efficacy, diminished adverse effects, and accordingly an improved therapeutic index. It is therefore, more desirable to use the (+) -isomer of bupropion for the conditions described herein.
  • abnormalities includes, but is not limited to seizures, dry mouth, insomnia, dizziness, restlessness, anxiety, agitation, headache/migraine, nausea/vomiting, constipation, tremor, delusions, tachycardia, hallucinations, psychotic episodes, blurred vision, confusion, paranoia, rashes and sleep disturbances .
  • substantially free of the term includes, but is not limited to seizures, dry mouth, insomnia, dizziness, restlessness, anxiety, agitation, headache/migraine, nausea/vomiting, constipation, tremor, delusions, tachycardia, hallucinations, psychotic episodes, blurred vision, confusion, paranoia, rashes and sleep disturbances .
  • (-) -stereoisomer as used herein means that the composition contains a greater proportion of the (+) -isomer of bupropion in relation to the (-) -isomer of bupropion.
  • the term "substantially free of its (-) -isomer” as used herein means that the composition contains at least 90% by weight of (+) -bupropion and 10% by weight or less of (-)- bupropion; or more preferably about 95% by weight of (+) - bupropion and 5% or less of its (-) -isomer. These percentages are based on the total amount of bupropion present in the composition.
  • the term "substantially free of the (-) -stereoisomer” means that the composition contains approximately 99% by weight of (+) -bupropion, and 1% or less of the (-) -bupropion.
  • the term “substantially free of its (+) -stereoisomer” as used herein means that the composition contains greater than 99% by weight of the (+) - isomer of bupropion, again based on the total amount of bupropion present.
  • the terms “substantially optically pure (+) -isomer of bupropion,” “optically pure (+) -isomer of bupropion” and " (+) -isomer of bupropion” are also encompassed by the above-described amounts.
  • a method of treating depression means relief from the symptoms of depression which include, but are not limited to changes in mood, feelings of intense sadness and despair, mental slowing, loss of concentration, pessimistic worry, agitation, and self- deprecation. Physical changes may also be relieved, including insomnia, anorexia and weight loss, decreased energy and libido, and the return of normal hormonal circadian rhythms .
  • AD attention deficit disorder
  • ADH attention deficit disorder with hyperactivity
  • DSM- III attention deficit/hyperactivity disorder
  • AD/HD attention deficit/hyperactivity disorder
  • treating Parkinson's disease means relief from the symptoms of Parkinson's disease which include, but are not limited to tremor, bradykinesia, rigidity, and a disturbance of posture.
  • treating obesity or weight gain in a human means reduction of weight or relief from being overweight or gaining weight due to extensive consumption of food and other factors including metabolism disorders .
  • (+) -isomer of bupropion may start from readily available 3 -chloropropiophenone (1) .
  • Reaction of (1) with a (2S , 3S) - ( -) -dialkyl tartrate such as (-) -dimethyl or diethyl tartrate in the presence of an acid catalyst such as methanesulfonic acid gives the chiral acetal (2) according to Castaldi (G. Castaldi, et al . , J. Org . Chem. 1987, 5.2: 3018).
  • bromoacetal (3) Steroselective bromination with bromine in carbon tetrachloride (or alternatively in ethyl acetate) then produces the corresponding bromoacetal (3) as the major product according to the above-referenced procedure developed by Castaldi and co-workers.
  • the bromoacetal (3) is purified by column chromatography to yield the optically pure bromoacetal (3) which is then hydrolyzed in the presence of an acid to afford the bromoketone (4) .
  • the optically pure isomers of bupropion can be prepared by another asymmetric route according to the procedures reported by Musso et al . , "Synthesis and Evaluation of the Antidepressant Activity of the Enantomers of Bupropion", Chirality 5:495-500 (1993) which is incorporated herein by reference in its entirety.
  • the stereoisomers of bupropion may be obtained by resolutions of a mixture of enantiomers of bupropion using conventional means such as an optically active resolving agent; see, for example, “Stereochemistry of Carbon Compounds", by E.L. Eliel (McGraw-Hill, NY, 1962), and S.H. Wilen, p. 268 in "Tables of Resolving Agents and Optical Resolutions” (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972) .
  • a prophylactic or therapeutic dose of (+) -bupropion in the acute or chronic management of disease will vary with the severity of the condition to be treated and its route of administration.
  • the dose and dose will vary with the severity of the condition to be treated and its route of administration.
  • the recommended daily dose range for the conditions described herein lies within the range of from about 10 mg to about 750 mg per day, generally divided equally into doses given three or four times a day.
  • a daily dose range should be between 50 mg and 600 mg per day, usually divided equally into a three or four times a day dosing.
  • a daily dose range should be between 60 mg and 450 mg per day, usually divided equally into a three times or a four times a day dosing. It may be necessary to use dosages outside these ranges in some cases. The physician will know how to increase, decrease or interrupt treatment based upon patient response.
  • any suitable route of administration may be employed for providing the patient with an effective dosage of (+) -bupropion.
  • oral, rectal, parenteral , transdermal, subcutaneous, intrathecal , intramuscular and the like may be employed as appropriate.
  • Dosage forms include tablets, coated tablets, caplets, capsules, troches, dispersions, sustained release formulations, suspensions, solutions, patches and the like.
  • compositions of the present invention comprise the (+) -isomer of bupropion as active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • acids include maleic, acetic, benzene-sulfonic (besylate) , benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Particularly preferred are hydrobromic, hydrochloric, phosphoric, and sulfuric acids.
  • compositions suitable for oral, rectal, and parenteral administration including subcutaneous, intrathecal, intramuscular, and intravenous
  • parenteral administration including subcutaneous, intrathecal, intramuscular, and intravenous
  • the most preferred route of the present invention is the oral route. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy .
  • a suitable dosage range for use is, e.g. , from about 10 mg to about 750 mg per day, generally divided equally into a three times a day dosing, preferably from about 50 mg to about 600 mg per day, generally divided equally into a three times a day dosing and most preferably from about 60 mg to about 450 mg per day, generally divided equally into a three times a day dosing.
  • Patients may be upward titrated from below to within this dose range to a satisfactory control of symptoms, or blood pressure as appropriate.
  • (+) -bupropion can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take
  • compositions for oral dosage form any of the usual pharmaceutical media may be employed, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, for example, suspensions, elixirs and solutions; or aerosols; or carriers such as starches, sugars, microcrystalline cellulose, stabilizers, diluents, granulating agents, lubricants, binders, fillers, disintegrating agents and the like in the case of oral solid preparations such as, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
  • any of the usual pharmaceutical media may be employed, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, for example, suspensions, elixirs and solutions; or aerosols; or carriers such as starches, sugars, microcrystalline cellulose, stabilizers, diluents, granul
  • the preferred solid oral preparation is tablets.
  • the most preferred solid oral preparation is coated tablets. Because of their ease of administration tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques .
  • compositions containing (+) -bupropion or salts thereof may also be used to stabilize compositions containing (+) -bupropion or salts thereof; acceptable stabilizers including but are not limited to L-cysteine hydrochloride, glycine hydrochloride, malic acid, sodium metabsulfite, citric acid, tartaric acid and L- cystine dihydrochloride . See, e.g., U.S. Patent No. 5,358,970 which is incorporated herein by reference.
  • the compounds of the present invention may also be administered by controlled release or sustained release means and/or delivery devices such as those described in U.S. Patent Nos . 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200, 4,008,719, 4,687,660, and 4 , 769 , 027 , the disclosures of which are hereby incorporated by reference.
  • Preferred controlled release or sustained released tablets are described in U.S. Patent Nos . 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200, 4,008,719, 4,687,660, and 4 , 769 , 027 , the disclosures of which are hereby incorporated by reference.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets or aerosol sprays, each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients.
  • compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with a binder, filler, lubricant, inert diluent, and/or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • each tablet contains from about 10 mg to about 250 mg of the active ingredient
  • each cachet or capsule contains from about 10 mg to about 250 mg of the active ingredient.
  • the tablet, cachet or capsule contains one of four dosages: about 50 mg, about 75 mg, about 100 mg and about 150 mg of active ingredient.
  • the water evaporates durinq manufacture .
  • the active ingredient is blended with the lactose until a uniform blend is formed.
  • the smaller quantity of corn starch is blended with a suitable quantity of water to form a corn starch paste. This is then mixed with said uniform blend until a uniform wet mass is formed.
  • the remaining corn starch is added to the resulting wet mass and mix until uniform granules are obtained.
  • the granules are then screened through a suitable milling machine, using a 1/4 inch stainless steel screen.
  • the milled granules are then dried in a suitable drying oven until the desired moisture content is obtained.
  • the dried granules are then milled through a suitable milling machine using 1/4 mesh stainless steel screen.
  • the magnesium stearate is then blended and the resulting mixture is compressed into tablets of desired shape, thickness, hardness and disintegration. Tablets are coated by standard aqueous or nonaqueous techniques.
  • Active ingredient 25 50 75 10 (+) -bupropion
  • Active ingredient 20 40 100 (+) -bupropion lactose BP 134, .5 114. .5 309. .0 30 starch BP 30, .0 30. .0 60. .0
  • the active ingredient is sieved through a suitable _ ⁇ sieve and blended with lactose, starch, and pregelatinized maize starch. Suitable volumes of purified water are added and the powders are granulated. After drying, the granules
  • Tablets of other strengths may be prepared by altering the ratio of active ingredient to lactose or the compression weight and using punches to suit.
  • (+) -Bupropion Hydrochloride is formulated using Contramid ® (Labopharm, Inc, Quebec) technology.
  • the formulation is prepared by blending the ingredients above (dry) and compressing into tablets.
  • the ingredients can be formulated using wet granulation technology known in the art. (See Example 1) .
  • (+) -Bupropion Hydrochloride is formulated using Contramid ® (Labopharm, Inc, Quebec) , technology.
  • the formulation is prepared by blending the ingredients above (dry) and compressing into tablets.
  • the ingredients can be formulated using wet granulation technology known in the art. (See Example 1) .
  • (+) -Bupropion Hydrochloride is formulated using Diffutab ® (Eurand, Microencapsulation, S.A. of Switzerland) technology. The formulation components are dry blended and directly compressed into tablets or formulated using wet granulation technology.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés et des compositions utilisant l'isomère (+) optiquement pur de bupropion, qui est un médicament puissant pour le traitement des dépressions, de la maladie de Parkinson, de l'obésité, de la prise de poids, des maladies à forme bipolaire, des troubles déficitaires de l'attention ou des troubles de conduite, des dysfonctionnements psychosexuels, de la boulimie, des troubles de l'alimentation ou d'une appétence de nourriture spécifique. Une telle composition peut être administrée par voie intraveineuse, par voie transdermique (timbre) ou par voie orale, éventuellement sous une forme à libération prolongée.
PCT/US1999/001952 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur WO1999038502A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002318960A CA2318960A1 (fr) 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur
AU24834/99A AU2483499A (en) 1998-01-29 1999-01-28 Pharmaceutical uses of optically pure (+)-bupropion
EP99904433A EP1051166A1 (fr) 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur
JP2000529235A JP2002501890A (ja) 1998-01-29 1999-01-28 光学的に純粋な（＋）−ビュープロピオンの薬学的使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7295598P 1998-01-29 1998-01-29
US60/072,955 1998-01-29

Publications (1)

Publication Number Publication Date
WO1999038502A1 true WO1999038502A1 (fr) 1999-08-05

Family

ID=22110794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001952 WO1999038502A1 (fr) 1998-01-29 1999-01-28 Utilisations pharmaceutiques de (+)-bupropion optiquement pur

Country Status (5)

Country Link
EP (1) EP1051166A1 (fr)
JP (1) JP2002501890A (fr)
AU (1) AU2483499A (fr)
CA (1) CA2318960A1 (fr)
WO (1) WO1999038502A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) * 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US8354453B2 (en) 2005-06-27 2013-01-15 Valeant International Bermuda Bupropion hydrobromide and therapeutic applications
WO2015095713A1 (fr) * 2013-12-20 2015-06-25 Deuterx, Llc Méthodes pour traiter des troubles neurologiques ou d'autres troubles au moyen de bupropion enrichi en deutérium énantiopure
US11179351B2 (en) 2018-09-20 2021-11-23 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) 2018-09-20 2022-05-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2019223187B2 (en) * 2018-02-23 2022-07-28 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) * 2018-09-20 2022-08-11 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) 2018-09-20 2022-09-06 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2020349419B2 (en) * 2019-09-20 2023-11-02 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US12180137B1 (en) 2024-05-01 2024-12-31 Deuterx, Llc Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016318A1 (fr) 2003-08-08 2005-02-24 Biovail Laboratories Inc. Comprime d'hydrochlorure de bupropion a liberation modifiee

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
WO1994004138A1 (fr) * 1992-08-14 1994-03-03 The Wellcome Foundation Limited Comprimes a liberation prolongee contenant du bupropione
WO1994020100A1 (fr) * 1993-03-02 1994-09-15 Nagle, John, S. Procede de traitement de maladie emotionnelle ou mentale, et maladie emotionnelle ou mentale concomitante a des crises
WO1995003791A1 (fr) * 1993-07-30 1995-02-09 The Wellcome Foundation Limited Composition pharmaceutique stabilisee contenant du bupropion
WO1996039133A1 (fr) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Nouvelles 2-amino-3'-4'-methylene-dioxypropiophenones n-substituees

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
WO1994004138A1 (fr) * 1992-08-14 1994-03-03 The Wellcome Foundation Limited Comprimes a liberation prolongee contenant du bupropione
WO1994020100A1 (fr) * 1993-03-02 1994-09-15 Nagle, John, S. Procede de traitement de maladie emotionnelle ou mentale, et maladie emotionnelle ou mentale concomitante a des crises
WO1995003791A1 (fr) * 1993-07-30 1995-02-09 The Wellcome Foundation Limited Composition pharmaceutique stabilisee contenant du bupropion
WO1996039133A1 (fr) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Nouvelles 2-amino-3'-4'-methylene-dioxypropiophenones n-substituees

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CRENSHAW ET AL.: "Pharmacological modification of psychosexual dysfunction", J. SEX. MARITAL THER., vol. 13, no. 4, 1987, pages 239 - 252, XP002107658 *
GARLAND ET AL.: "Pharmacotherapy of adolescent attention deficit hyperactivity disorder : challenges, choices and caveats", J. PSYCHOPHARMACOLOGY, vol. 12, no. 4, 4 December 1998 (1998-12-04), pages 385 - 395, XP002107659 *
MCNAMEE ET AL.: "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. PHARM. PHARMACOL., RECD 1986, vol. 37, no. suppl., 1985, pages 147p, XP002107660 *
MUSSO ET AL.: "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", CHIRALITY, vol. 5, no. 7, 1993, pages 495 - 500, XP002107656 *
WRIGHT ET AL.: "Bupropion in the long-term treatment of cyclic mood disorders : mood stabilizing effects", J. CLIN. PSYCHIATRY, vol. 46, no. 1, 1985, pages 22 - 25, XP002107634 *
ZARRINDAST ET AL.: "Anorectic and behavioral effects of bupropion", GEN. PHARMACOLOGY, vol. 19, no. 2, 1988, pages 201 - 204, XP002107657 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) * 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
RU2408368C2 (ru) * 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
EP1896002A2 (fr) * 2005-06-27 2008-03-12 Biovail Laboratories International Srl Formulations a liberation modifiee d'un sel de bupropion
WO2007002597A3 (fr) * 2005-06-27 2009-04-23 Biovail Lab Int Srl Formulations a liberation modifiee d'un sel de bupropion
EP1896002A4 (fr) * 2005-06-27 2009-11-25 Biovail Lab Int Srl Formulations a liberation modifiee d'un sel de bupropion
US9504640B2 (en) 2005-06-27 2016-11-29 Valeant Pharmaceuticals Luxembourg S.Á.R.L. Modified release formulations of a bupropion salt
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
AU2006261788B2 (en) * 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
EP2474308A1 (fr) * 2005-06-27 2012-07-11 Valeant International (Barbados) SRL Formulations pharmaceutiques contenant l'hydrobromure de bupropion
EP2502621A1 (fr) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Formes cristallines de bupropine HBr
US8354453B2 (en) 2005-06-27 2013-01-15 Valeant International Bermuda Bupropion hydrobromide and therapeutic applications
KR101306635B1 (ko) * 2005-06-27 2013-10-11 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온염의 개질-방출 제형
US8932628B2 (en) 2005-06-27 2015-01-13 Valeant International Bermuda Modified release formulations of a bupropion salt
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US9732031B2 (en) 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
WO2015095713A1 (fr) * 2013-12-20 2015-06-25 Deuterx, Llc Méthodes pour traiter des troubles neurologiques ou d'autres troubles au moyen de bupropion enrichi en deutérium énantiopure
AU2019223187B2 (en) * 2018-02-23 2022-07-28 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2022204521B2 (en) * 2018-02-23 2024-09-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) * 2018-09-20 2022-08-11 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11344514B2 (en) 2018-09-20 2022-05-31 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11344513B2 (en) 2018-09-20 2022-05-31 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11179352B2 (en) 2018-09-20 2021-11-23 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) 2018-09-20 2022-09-06 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) 2018-09-20 2022-05-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20230248669A1 (en) * 2018-09-20 2023-08-10 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20230248668A1 (en) * 2018-09-20 2023-08-10 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11786488B2 (en) 2018-09-20 2023-10-17 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US12102606B2 (en) 2018-09-20 2024-10-01 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11179351B2 (en) 2018-09-20 2021-11-23 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2020349419B2 (en) * 2019-09-20 2023-11-02 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US12180137B1 (en) 2024-05-01 2024-12-31 Deuterx, Llc Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof

Also Published As

Publication number Publication date
JP2002501890A (ja) 2002-01-22
EP1051166A1 (fr) 2000-11-15
AU2483499A (en) 1999-08-16
CA2318960A1 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
US5104899A (en) Methods and compositions for treating depression using optically pure fluoxetine
WO1999038502A1 (fr) Utilisations pharmaceutiques de (+)-bupropion optiquement pur
US5589511A (en) Method for treating migraine headaches using optically pure S(+) fluoxetine
US20030130355A1 (en) Therapeutic agents
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2001503737A (ja) 糖尿病の発生を防止するためのシブトラミン類似体の利用
EP0687472A2 (fr) Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
CA2138998A1 (fr) Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (-)
AU4542993A (en) Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
EP0612242B1 (fr) Utilisation de l' isomere s(+) pur de fluoxetine pour la preparation d'un medicament contre la migraine
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1992013452A1 (fr) Procedes d'utilisation et compositions de r(-) fluoxetine
JP2002539250A (ja) 肺高血圧症の治療
AU6172699A (en) Methods and compositions utilizing pure S()isomer fluoxetine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2318960

Country of ref document: CA

Ref country code: CA

Ref document number: 2318960

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 24834/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 529235

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999904433

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999904433

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999904433

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999904433

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载